Q-omics provides the consensus-scored TGFB3 profile across patient tissues and cancer cell-line models. TGFB3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TGFB3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TGFB3 protein abundance shows 20,424 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, HNSC, and PDAC as cancer lineages where TGFB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGFB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGFB3 survival associations across molecular data types. TGFB3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGFB3 RNA expression–survival associations across cancer types. High TGFB3 expression shows unfavorable associations in BLCA, KIRP, ACC, LGG and COAD, but favorable associations in BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TGFB3 RNA expression.
This table summarizes TGFB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TGFB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGFB3 shows lower tumor expression in KICH and BLCA and higher tumor expression in HNSC, KIRC, BRCA and CHOL. The HNSC box plot shows higher TGFB3 RNA expression in tumor versus normal tissue (log2 FC = +1.486, t-test p < 0.001).
This table shows molecular features associated with TGFB3 in patient tissues and cancer cell lines. In patient samples, TGFB3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TGFB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
